Vomiting
Conditions
Interventions
This is a randomized, triple-blind, placebo-controlled clinical trial. The sample of this study will consist of 104 participants for each group. The experimental group (will use the service's usual an
E02.190
Sponsors
Escola de Enfermagem de Ribeirão Preto da Universidade de São Paulo
Escola de Enfermagem de Ribeirão Preto da Universidade de São Paulo
Eligibility
Sex/Gender
Female
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Women. Be undergoing curative antineoplastic chemotherapy treatment, regardless of the histological type and staging of the tumor. Have undergone at least one cycle of chemotherapy. Have at least two cycles of chemotherapy to be performed. Be using a chemotherapy protocol that has emetic potential. Be aged 18 or over. Be in a physical and cognitive condition to understand the Free and Informed Consent Form and to participate in the study by responding to the Morrow scale instrument and the sociodemographic and clinical questionnaire form
Exclusion criteria
Exclusion criteria: Being delirious or mentally confused. Be on other types of cancer treatment, other than just antineoplastic chemotherapy. Have injuries or allergic processes on the face. Being pregnant. Have a history of chronic obstructive pulmonary disease, asthma or other respiratory disorder that may be exacerbated by strong odors, inability to smell fragrances, allergy or sensitivity to peppermint or any strong odor. Use another integrative therapy to treat chemotherapy-induced nausea and vomiting during the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence and intensity of chemotherapy-induced nausea and vomiting. | — |
Secondary
| Measure | Time frame |
|---|---|
| No secondary outcomes are expected | — |
Countries
Brazil
Contacts
Public ContactKárita da Mota
Escola de Enfermagem de Ribeirão Preto da Universidade de São Paulo
Outcome results
None listed